Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 18/20 | 0.65 |
| ▸ | BACE1 | P56817 | 16/20 | 0.65 |
| ▸ | BACE2 | Q9Y5Z0 | 14/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223981 | 0.94 | CTSD (0.64) | CTSDBACE1BACE2 | |
| SCHEMBL5224553 | 0.94 | CTSD (0.64) | CTSDBACE1BACE2 | |
| SCHEMBL5220783 | 0.91 | CTSD (0.64) | CTSDBACE1 | |
| SCHEMBL5218938 | 0.91 | CTSD (0.76) | CTSDBACE1BACE2CYP3A4CYP2D6 | |
| SCHEMBL5219799 | 0.89 | CTSD (0.67) | CTSDBACE1BACE2CYP3A4CYP2D6 | |
| SCHEMBL5220220 | 0.87 | CTSD (0.70) | CTSDBACE1BACE2CYP3A4CYP2D6 | |
| SCHEMBL5222800 | 0.87 | BACE1 (0.83) | CTSDBACE1BACE2CYP3A4CYP2D6 | |
| SCHEMBL5217481 | 0.87 | CTSD (0.66) | CTSDBACE1BACE2CYP3A4CYP2D6 | |
| SCHEMBL5222793 | 0.87 | BACE1 (0.83) | CTSDBACE1BACE2CYP3A4CYP2D6 | |
| SCHEMBL5220781 | 0.86 | BACE1 (0.62) | CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | claimed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | claimed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | claimed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | CTSD 384/4885BACE1 3/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.